Company intelligence / Profile preview

Ausvic Capital

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

Ausvic Capital is a Hong Kong-based private investment and venture capital firm founded in 2018. The firm invests across biotechnology, digital economy, artificial intelligence, cloud computing, blockchain, and related technology sectors rather than operating as a drug developer or healthcare services company. Public profiles describe it as an active investor led by founding partner Ping Chen, with portfolio activity spanning both biotech and non-health technology companies. Based on available evidence, Ausvic Capital should be classified primarily as an investment firm with some life-science exposure, not as a biotech, pharma, or healthcare operating company.

Industry: Investors

Beyond the preview

Go deeper on Ausvic Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ausvic Capital.

Explore the full profile